Nov 25, 2021 08:39 PM (GMT+8) · EqualOcean
Lanfan medical announced that the innovative product "implantable left ventricular assist system" developed by Tongxin Medical Institute of the joint-stock company obtained the registration license of class III devices from the State Drug Administration today. The system is used together with specific artificial blood vessels to provide mechanical support for blood circulation in patients with advanced refractory left heart failure, and is used for transitional treatment before heart transplantation or restoration of heart function.